JP2019501199A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501199A5 JP2019501199A5 JP2018535385A JP2018535385A JP2019501199A5 JP 2019501199 A5 JP2019501199 A5 JP 2019501199A5 JP 2018535385 A JP2018535385 A JP 2018535385A JP 2018535385 A JP2018535385 A JP 2018535385A JP 2019501199 A5 JP2019501199 A5 JP 2019501199A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- oral dosage
- form according
- ratio
- powder dispersion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006186 oral dosage form Substances 0.000 claims description 18
- 239000006185 dispersion Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 7
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 7
- 239000008109 sodium starch glycolate Substances 0.000 claims description 7
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims 5
- 229960003604 testosterone Drugs 0.000 claims 3
- 229960000746 testosterone undecanoate Drugs 0.000 claims 3
- UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 206010002261 Androgen deficiency Diseases 0.000 claims 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 201000007493 Kallmann syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010053142 Olfacto genital dysplasia Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 238000009165 androgen replacement therapy Methods 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 239000008199 coating composition Substances 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 201000003585 eunuchism Diseases 0.000 claims 1
- 230000009246 food effect Effects 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000037106 male hypogonadism Diseases 0.000 claims 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000006584 pituitary dysfunction Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 229940071117 starch glycolate Drugs 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276452P | 2016-01-08 | 2016-01-08 | |
| US62/276,452 | 2016-01-08 | ||
| US201662394576P | 2016-09-14 | 2016-09-14 | |
| US62/394,576 | 2016-09-14 | ||
| PCT/US2017/012739 WO2017120592A1 (en) | 2016-01-08 | 2017-01-09 | Proliposomal testosterone undecanoate formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019501199A JP2019501199A (ja) | 2019-01-17 |
| JP2019501199A5 true JP2019501199A5 (enExample) | 2020-02-13 |
Family
ID=59274044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535385A Pending JP2019501199A (ja) | 2016-01-08 | 2017-01-09 | プロリポソームテストステロンウンデカノエート製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190248830A1 (enExample) |
| EP (1) | EP3399965A4 (enExample) |
| JP (1) | JP2019501199A (enExample) |
| KR (1) | KR20180101452A (enExample) |
| CN (1) | CN108601736A (enExample) |
| WO (1) | WO2017120592A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
| RU2623206C2 (ru) | 2005-04-15 | 2017-06-22 | Кларус Терапьютикс, Инк. | Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих |
| ES3006512T3 (en) | 2017-11-17 | 2025-03-18 | Evonik Operations Gmbh | Process for preparing a coated hard shell capsule |
| US12150945B2 (en) * | 2018-07-20 | 2024-11-26 | Lipocine Inc. | Liver disease |
| US20200197413A1 (en) * | 2018-12-20 | 2020-06-25 | Clarus Therapeutics, Inc. | Methods of treating testosterone deficiency |
| MX2022001417A (es) * | 2019-08-09 | 2022-06-08 | Tesorx Pharma Llc | Formulaciones de undecanoato de testosterona proliposomal. |
| GB202307501D0 (en) * | 2023-05-19 | 2023-07-05 | Lawley Pharmaceuticals Pty Ltd | Process for preparing dispensable testosterone cream |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6759058B1 (en) * | 2001-04-25 | 2004-07-06 | Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences | Enteric-coated proliposomal formulations for poorly water soluble drugs |
| WO2008000534A1 (de) * | 2006-06-30 | 2008-01-03 | Gertrud Langhoff | Solubilisatformulierungen |
| WO2008114274A1 (en) * | 2007-03-19 | 2008-09-25 | Fresenius Kabi Onclology Ltd. | Proliposomal and liposomal compositions |
| EP2229936B1 (en) * | 2009-03-09 | 2015-05-06 | PharmaSol GmbH | Nanonized testosterone formulations for improved bioavailability |
| US20140309202A1 (en) * | 2010-11-30 | 2014-10-16 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| SG11201407349UA (en) * | 2012-05-09 | 2014-12-30 | Univ Western Health Sciences | Proliposomal testosterone formulations |
-
2017
- 2017-01-09 KR KR1020187022494A patent/KR20180101452A/ko not_active Withdrawn
- 2017-01-09 JP JP2018535385A patent/JP2019501199A/ja active Pending
- 2017-01-09 EP EP17736520.2A patent/EP3399965A4/en not_active Withdrawn
- 2017-01-09 US US16/068,190 patent/US20190248830A1/en not_active Abandoned
- 2017-01-09 WO PCT/US2017/012739 patent/WO2017120592A1/en not_active Ceased
- 2017-01-09 CN CN201780010451.5A patent/CN108601736A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501199A5 (enExample) | ||
| CN113767106A (zh) | 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途 | |
| CA2845806C (en) | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof | |
| JP7332293B2 (ja) | バルリチニブおよび抗癌剤を含んでなる併用療法 | |
| JP7025416B2 (ja) | 好中球減少症を低減させるための組成物および方法 | |
| JP7350015B2 (ja) | プリナブリンの投与による血小板減少症を軽減するための組成物および方法 | |
| RU2011123876A (ru) | Антисмысловые композиции и способы их получения и применения | |
| JP2015505565A5 (enExample) | ||
| JP6002835B2 (ja) | 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| JP2010502762A5 (enExample) | ||
| JP2011511071A5 (enExample) | ||
| RU2017127088A (ru) | Комбинация ингибиторов чекпойнт-киназы 1 и ингибиторов киназы wee 1 | |
| JP2018527392A5 (enExample) | ||
| JP2015057436A5 (enExample) | ||
| JP2014524469A5 (enExample) | ||
| CN102076215A (zh) | 5-氟胞嘧啶制剂及其用途 | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| JP2019517542A5 (enExample) | ||
| JP2013518124A5 (enExample) | ||
| RU2014141893A (ru) | Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких | |
| JP2013508289A5 (enExample) | ||
| JP2017513809A5 (enExample) | ||
| CN115624564A (zh) | 用于递送抗病毒剂的药物递送系统 | |
| JP2015522603A5 (enExample) | ||
| CN105025888B (zh) | 肠溶片 |